Connexon Creative - Mammary Cell News 1.20, October 1st, 2009

In this issue: Science News | Current Publications | Industry News | Policy News | Events

TOP STORIES

Social Isolation Adversely Affects Breast Cancer
A socially isolated, stressful environment can speed up the growth of breast cancer, reported researchers studying the effects of stress in animal models. In mouse study, those living alone had larger tumors than those in groups. [Ben May Department for Cancer Research, University of Chicago, Chicago]

SPECIAL FEATURE

Mammary Epithelial Cell Colony Interactive Tutorial
Explore interactive bi-potent colonies and highlight luminal and basal structures in 3D morphogenesis structures.
Try tutorial now

SCIENCE NEWS

Therapeutic Nanoparticles Give New Meaning to Sugar-Coating Medicine
A research team study how special sugar coated iron oxide nanoparticles interact with each other to destroy cancer cells under laboratory conditions. [National Institute of Standards and Technology, Boulder]

Penn Studies Point To Strategies for Reducing Painful Breast Cancer Drug Side Effects
Researchers found that estrogen withdrawal may play a role in the onset of joint pain, also known as arthralgia, during treatment with aromatase inhibitor cancer drugs. [Penn's Abramson Cancer Center, Philadelphia]

Medications Effective in Reducing Risk of Breast Cancer but Increase Risk of Adverse Effects, New Report Says
Study is the first to make a direct, comprehensive comparison of drugs that reduce the risk of breast cancer (tamoxifen, raloxifene and tibolone) so that women and their health care providers can assess their potential effectiveness and adverse effects. [Agency for Healthcare Research and Quality, Rockville]

Sorafenib/Capecitabine Combo Boosts Progression-Free Survival In Advanced Breast Cancer
The potent oral multiple kinase inhibitor sorafenib (NexavarR) combined with the chemotherapy drug capecitabine (XelodaR) significantly improves progression-free survival (PFS) over capecitabine alone in patients with locally advanced or metastatic HER-2 negative breast cancer. [d'Hebron Institute of Oncology, Barcelona]

CURRENT PUBLICATIONS

LABORATORY RESEARCH

Loss of ALX4 Expression in Epithelial Cells and Adjacent Stromal Cells in Breast Cancer
Data show a distinct pattern of expression of ALX4 in the human breast relative to the murine mammary gland. Furthermore, characterization of ALX4 in breast cancer showed that loss of ALX4 in tumours and the surrounding untransformed stroma is a basic characteristic of DCIS and IDC. [J Clin Pathol]

Mitogen-Activated Protein Kinase Signalling in Experimental Models of Breast Cancer Progression and in Mammary Gland Development
Although less well studied, researchers highlight the instances of signaling through the p38 and JNK pathways with breast cancer progression and mammary gland development. [Breast Cancer Res]

The Membrane Mucin MUC4 is Elevated in Breast Tumor Lymph Node Metastases Relative to Matched Primary Tumors and Confers Aggressive Properties to Breast Cancer Cells
After an initial loss of MUC4 levels during the transition of normal breast tissue to primary tumor, the re-establishment of elevated MUC4 levels confers an advantage to metastasizing breast tumor cells by promoting the acquisition of cellular properties associated with malignancy. [Breast Cancer Res]

Ovarian Hormones are Not Required for PRL-Induced Mammary Tumorigenesis, but Estrogen Enhances Neoplastic Processes
Findings indicate that prolactin (PRL) employs multiple mechanisms to promote mammary tumorigenesis. [J Endocrinol]

CLINICAL RESEARCH

Patterns and Risk Factors Associated With Aromatase Inhibitor-Related Arthralgia Among Breast Cancer Survivors
Aromatase Inhibitor Arthralgia (AIA) is common, beginning within the first 3 months of therapy in most patients, and appeared to be related inversely to the length of time since cessation of menstrual function. Findings suggest that estrogen withdrawal may play a role in the mechanism of this disorder. [Cancer]

INDUSTRY NEWS

Celsion Corporation Initiates Enrollment Awareness Program for Pivotal Phase I/II DIGNITY Trial of ThermoDox(R) in Patients with Recurrent Chest Wall (RCW) Breast Cancer
Celsion Corporation announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox(R) in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer.

POLICY NEWS

NIH State-of-the-Science Conference: Diagnosis and Management of Ductal Carcinoma in Situ (DCIS)
To provide health care providers, patients, and the general public with a responsible assessment of currently available data on the diagnosis and management of ductal carcinoma in situ (DCIS).

EVENTS

2009 National Cancer Research Institute Conference
October 4-7, 2009
Birmingham, United Kingdom

Global Breast Cancer Conference
October 8-10, 2009
Seoul, South Korea

AACR - Advances in Breast Cancer Research
October 13-16, 2009
San Diego, CA, United States

32nd Annual CTRC - AACR San Antonio Breast Cancer Symposium
December 9-13, 2009
San Antonio, TX

Gordon Research Conference - Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Learn more about Mammary Cell News: Archives | Events | Update Profile | Contact Us

This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada